Denmark-based Liva Healthcare secures €24.5M funding to provide digital health and lifestyle coaching for chronic disease prevention and management
The on-going coronavirus-19 pandemic has forever changed the way we receive healthcare. This shift in acceptance and the subsequent patient behavior has led to the rise in the adoption of telemedicine, virtual doctors, and other telehealth services including health education services, remote monitoring of vital signs, ECG or blood pressure, and remote doctor-patient consultations.
It is no different in Europe. The pandemic has led to a significant shift in the acceptance of remote healthcare by European consumers. Tech startups in Europe are quick to embrace the change. One of the leading startups in scalable digital health coaching is Denmark-based Liva Healthcare.
Liva is a health tech startup headquartered in Copenhagen and London with the mission to improve the lives of people at risk of, or living with, chronic conditions such as Type 2 diabetes, obesity, and heart diseases by driving positive behavioral change. Liva blends scalable health coaching focused on personal human relationships with an intuitive and user-friendly interface. Liva was founded in 2015 by the team behind independent health information portal NetDoctor.com.
Today, Liva announced it has secured a new funding round of €24.5 million, led by Verlinvest, the go-to investor for mission-driven entrepreneurs and category-defining global consumer brands. The investment will enable Liva to strengthen its position as a European leader in digital health and lifestyle coaching for chronic disease prevention and management.
Founded in 2014 by Carl Brandt, Kristoffer From, and Rune Bech, Liva Healthcare’s platform facilitates ongoing personalized health coaching through an intuitive app, building a strong bond between a coach, GP, and patient. Its focus lies on tackling chronic illnesses, such as Type 2 diabetes, obesity, and heart disease by driving behavior change.
Liva is used by major companies including Novo Nordisk, AXA Health, Amgen, City of Copenhagen, Bupa Australia, and several other key players in public healthcare, insurance, and life science industries globally. Liva is also a partner to NHS England on its world-leading National Diabetes Prevention Programme. Liva is currently operational in Britain, Australia, Ireland, Holland, Belgium, Denmark, Sweden, and Finland with operations currently being set up in Germany and Switzerland.
“This new funding, from one of Europe’s strongest purpose-led, consumer growth investors, will substantially accelerate our expansion in core European markets,” says André Sode, CEO of Liva Healthcare. “COVID-19 has demonstrated how effective remote digital health solutions can be. With healthcare providers around the world looking for scalable solutions to combat the rise in diabetes and obesity, we are ideally placed to support and have experienced a significant increase in interest as a result.”
“This investment represents a major new entry into digital health for Verlinvest, where technology is fuelling consumer revolutions,” says Simone Sallustio, Executive Director at Verlinvest. “Digital healthcare has been vital in getting treatment to patients during the pandemic and this trend will continue as effective virtual programs give people more flexible healthcare options. Liva’s advanced technology and proven clinical outcomes set it apart from its competitors. In this exciting and rapidly evolving space, Liva’s experience and established partnerships represent a strategic choice for Verlinvest.”